APA (7th ed.) Citation

Moreno, V., Luke, J., Gelmon, K., Joshua, A., Varga, A., Desai, J., . . . Tabernero, J. (2019). 1116 - Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup. European Urology Supplements, 18(1), e1509. https://doi.org/10.1016/S1569-9056(19)31087-5

Chicago Style (17th ed.) Citation

Moreno, V., et al. "1116 - Combination of the Indoleamine 2,3-dioxygenase 1 Inhibitor (IDO1i) BMS-986205 with Nivolumab (nivo): Updated Safety Across All Tumors and Efficacy in Advanced Bladder Cancer (advBC) by Patient (pt) Subgroup." European Urology Supplements 18, no. 1 (2019): e1509. https://doi.org/10.1016/S1569-9056(19)31087-5.

MLA (9th ed.) Citation

Moreno, V., et al. "1116 - Combination of the Indoleamine 2,3-dioxygenase 1 Inhibitor (IDO1i) BMS-986205 with Nivolumab (nivo): Updated Safety Across All Tumors and Efficacy in Advanced Bladder Cancer (advBC) by Patient (pt) Subgroup." European Urology Supplements, vol. 18, no. 1, 2019, p. e1509, https://doi.org/10.1016/S1569-9056(19)31087-5.